Silverback Therapeutics, Inc. (SBTX)
|Net Income (ttm)||-26.83M|
|Trading Day||January 15|
|Day's Range||48.20 - 54.41|
|52-Week Range||25.00 - 54.41|
Silverback Therapeutics Inc (NASDAQ: SBTX) recently raised $277.7 million by selling 13.225 million shares in an initial public offering that were priced at $21 each. The Silverback Analyst: S...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to de...
The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education & Technology Group. Two companies, Ondas and A...
The hot category of initial public offerings in the biotechnology sector continues, with two set to trade Friday: Seer and Silverback Therapeutics. Both priced above their estimated range.
Silverback Therapeutics will raise $241.
SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemica...
Silverback Therapeutics Inc. upsized its initial public offering to 10.00 million shares, and the expected pricing of the offering increased to between $19 and $20 a share. The Seattle-based b...
Seattle, Washington-based Silverback was founded to create what it calls its ImmunoTAC platform to develop 'systematically delivered, tissue targeted therapeutics' by pairing 'proprietary link...
The signs were there: A couple of months ago, Silverback Therapeutics quickly pulled in $163 million in two back-to-back rounds for what CEO Laura Shawver called “an important growth phase.” A...
Silverback Therapeutics is on a roll. After banking more than $160 million in venture capital this year, the immuno-oncology biotech filed on Tuesday to raise up to $100 million in its Wall St...
Silverback Therapeutics filed for an initial public offering on Tuesday, seeking additional capital as it develops targeted therapeutics for cancer, viral infections and other diseases, led by...
Silverback Therapeutics, a Phase 1 biotech developing therapeutics for solid tumors and other diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Silverback Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Silverback Therapeutics, a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-... [Read more...]
|IPO Date |
Dec 4, 2020
|Stock Exchange |
|Ticker Symbol |
According to 4 analysts, the average rating for SBTX stock is "Buy." The 12-month stock price forecast is 46.25, which is a decrease of -4.28% from the latest price.